Latest Stock Market News

Glenmark Pharmaceuticals, incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 17198.15 Crore) operating in Pharmaceuticals sector.

Promoters held 0.0 per cent stake in the company as of 31-Mar-2023, while FII and DII ownership stood at 7.01 per cent and 3.29 per cent, respectively.

A total of 39,400 shares changed hands on the counter till 12:25PM (IST).

So first and foremost at the outset, the Q4 was a decent quarter. In terms of our sales growth, we did about Rs 3370 crores and almost 11.7% growth and EBITDA margin of almost 17.9%. I think the coming year we are quite optimistic about touching about 19-20% based on a couple of things; one obviously is we expect the revenue to grow at about 10-11%.

A total of 2,056 shares changed hands on the counter till 10:25AM (IST).

Brent has softened considerably to ~USD75/bbl in May’23YTD from USD96/bbl in FY23, which bodes well for the stock. BPCL trades at 1.3x FY24E PBV, and we value the stock at 1.2x FY25E P/BV to arrive at our TP of INR 360.

As far as PNB is concerned, first, you see our provisional coverage ratio which was around 81% in the last year March 22 has improved to 86.90%, this is giving the comfort to us.

The stock quoted a 52-week high price of Rs 10760.4 and low of Rs 5708.1.

Vivriti Asset Management has secured debt financing from the International Finance Corporation and an anchor commitment from M&G Catalyst for its asset-backed securities fund, which has a target size of $250m. The Vivriti India Retail Asset Fund has already raised $106m from the two investors. Over the 10-year period, the fund will funnel international capital towards non-banking financial companies specialising in small- and medium-sized enterprise finance, used vehicle finance and microfinance.

On the technical charts, the RSI of the stock stood at 77.48.